Vaccinex, Inc. Announces Special Meeting for Reverse Stock Split Approval

TL;DR

<b>Vaccinex, Inc. is seeking stockholder approval for a reverse stock split with a flexible ratio, to be decided by the board.</b>

AI Summary

VACCINEX, INC. (VCNX) filed a Proxy Statement (DEF 14A) with the SEC on January 8, 2024. Vaccinex, Inc. will hold a special meeting on February 8, 2024, to vote on a reverse stock split. Stockholders will consider approving amendments to the Certificate of Incorporation for a reverse stock split. The reverse stock split ratio can range from one-for-four to one-for-fourteen shares. The board of directors will have the final decision on the reverse stock split ratio and timing, up to one year after stockholder approval. The record date for determining eligible stockholders is December 29, 2023.

Why It Matters

For investors and stakeholders tracking VACCINEX, INC., this filing contains several important signals. The reverse stock split is likely intended to increase the per-share price of the company's stock, potentially to meet exchange listing requirements or improve investor perception. Granting the board discretion over the final ratio and timing allows for flexibility in responding to market conditions or strategic needs before the one-year approval window closes.

Risk Assessment

Risk Level: medium — VACCINEX, INC. shows moderate risk based on this filing. The company is seeking approval for a reverse stock split, which can be a signal of financial distress or a move to avoid delisting, indicating potential underlying business challenges.

Analyst Insight

Stockholders should carefully consider the implications of a reverse stock split on their investment and the company's future prospects before voting.

Key Numbers

• 1-for-4 to 1-for-14 — Reverse Stock Split Ratio Range (Possible ratios for the reverse stock split)
• 1 year — Board Discretion Period (Period for board to determine reverse stock split details)
• 10:00 a.m. ET — Meeting Time (Time of the Special Meeting)

Key Players & Entities

• VACCINEX, INC. (company) — Registrant
• February 8, 2024 (date) — Date of Special Meeting
• December 29, 2023 (date) — Record date for stockholders
• Maurice Zauderer (person) — President and Chief Executive Officer
• 1895 Mount Hope Ave, Rochester, NY 14620 (address) — Corporate headquarters

Forward-Looking Statements

• Vaccinex's board of directors will likely approve a reverse stock split to maintain exchange listing compliance. (VACCINEX, INC.) — high confidence, target: 2024-02-08

FAQ

Risk Factors

• Reverse Stock Split Approval [medium — financial]: Stockholders are asked to approve amendments to the Certificate of Incorporation to effect a reverse stock split, with the board having discretion over the ratio and timing.

Industry Context

Vaccinex, Inc. operates in the pharmaceutical preparations industry, specifically focusing on drug development.

Regulatory Implications

The filing is a Definitive Proxy Statement (DEF 14A) filed under the Securities Exchange Act of 1934, detailing proposals for stockholder vote.

What Investors Should Do

1. Review the proxy statement thoroughly to understand the implications of the proposed reverse stock split.
2. Vote on the proposed amendments to the Certificate of Incorporation regarding the reverse stock split.
3. Monitor future filings for decisions made by the board regarding the reverse stock split ratio and implementation.

Key Dates

• 2024-02-08: Special Meeting of Stockholders — To vote on proposed reverse stock split
• 2023-12-29: Record Date — Determines stockholders eligible to vote
• 2024-01-08: Filing Date — Date the DEF 14A filing was made

Year-Over-Year Comparison

This is a DEF 14A filing, indicating a proxy statement for a special meeting, distinct from routine quarterly or annual reports.

Key Financial Figures

• $0.0001 — s outstanding, designated common stock, $0.0001 par value per share. Each stockholder o
• $1.00 — ice for our common stock had been below $1.00 for the previous 30 consecutive busines
• $1 — by February 20, 2024, and maintaining a $1 or more per share closing bid price for
• $0.6648 — ce of one share of our common stock was $0.6648. The Reverse Stock Split, if effected,

Filing Documents

• d578290ddef14a.htm (DEF 14A) — 206KB
• g578290dsp7.jpg (GRAPHIC) — 1KB
• g578290dsp7a.jpg (GRAPHIC) — 2KB
• g578290g01a03.jpg (GRAPHIC) — 53KB
• g578290log1.jpg (GRAPHIC) — 4KB
• 0001193125-24-004424.txt (&nbsp;) — 291KB

SECURITY OWNERSHIP OF MANAGEMENT AND CERTAIN BENEFICIAL OWNERS

SECURITY OWNERSHIP OF MANAGEMENT AND CERTAIN BENEFICIAL OWNERS 18 OTHER MATTERS 20 Table of Contents VACCINEX, INC. PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why am I receiving these materials? The board of directors (the Board) of Vaccinex, Inc. (Vaccinex, the Company, we, our, or us), a Delaware corporation, is providing these proxy materials to you, and is soliciting the enclosed proxy, for use at the special meeting of stockholders (the Special Meeting) to be held on Thursday, February 8, 2024 at 10:00 a.m., Eastern Time, or at any adjournment of the meeting, for the purposes set forth in this proxy statement and in the accompanying notice of special meeting of stockholders. The Special Meeting will be held at our corporate headquarters, located at 1895 Mount Hope Avenue, Rochester, New York 14620. We are first mailing these proxy solicitation materials to stockholders on or about January 8, 2024. What is householding and how does it impact me? With regard to the delivery of Proxy Statements and Annual Reports, under certain circumstances the SEC permits a single set of these documents or, where applicable, one notice, to be sent to any household at which two or more stockholders reside if they appear to be members of the same family. Each stockholder, however, still receives a separate proxy card. This procedure, known as householding, reduces the amount of duplicate information received at a household and reduces delivery and printing costs as well. A number of banks, brokers and other firms have instituted householding and have previously sent a notice to that effect to certain of our stockholders whose shares are registered in the name of the bank, broker or other firm. As a result, unless the stockholders receiving the notice gave contrary instructions, only one Annual Report and/or Proxy

View Full Filing

View this DEF 14A filing on SEC EDGAR